However, patients with low CTU2 levels demonstrated a higher likelihood of responding to immunotherapy, as evidenced by improved prognosis in melanoma and renal cell carcinoma when treated with anti-PD-1 therapy, compared to those with high CTU2 levels (Figures 6A, B). The gene discussed is PDCD1; the disease is hereditary clear cell renal cell carcinoma.